MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
416.76%
Quick Ratio
389.00%
Cash Ratio
60.21%
Debt to Asset Ratio
46.28%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Accounts receivable, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Series a convertible preferred s...
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
62,137 54,301 52,078 135,586
Short-term investments
278,488 334,648 363,974 155,444
Accounts receivable, net
34,192 26,081 33,034 26,122
Inventory
28,651 25,753 22,107 18,872
Prepaid expenses and other current assets
26,622 26,133 23,609 24,656
Total current assets
430,090 466,916 494,802 360,680
Property and equipment, net
1,065 1,104 237 297
Right-of-use asset
2,936 3,049 3,158 3,262
Intangible assets, net
5,106 5,319 5,533 5,747
Restricted cash
601 522 671 527
Other long-term assets
2,518 3,286 2,473 2,220
Total assets
442,316 480,196 506,874 372,733
Accounts payable
12,299 13,947 13,631 15,982
Accrued expenses and other current liabilities
80,045 83,855 84,456 69,185
Other current liability - lg chem
NaN 0 NaN 40,000
Lease liability
676 650 624 510
Deferred revenue
48 194 NaN NaN
Deferred royalty obligation, current
10,130 7,296 5,556 3,778
Total current liabilities
103,198 105,942 104,267 129,455
Deferred royalty obligation
98,339 100,886 103,409 106,014
Lease liability, non-current
3,163 3,342 3,515 3,681
Derivative liability
NaN 0 NaN NaN
Total liabilities
204,700 210,170 211,191 239,150
Series a convertible preferred stock, 0.001 par value 150,000 shares authorized 132,500 and 132500 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively. liquidation preference of 132,500 and 132,500 as of march 31, 2026, and december 31, 2025, respectively
114,710 130,957 146,866 145,491
Common stock, 0.001 par value 120,000,000 shares authorized 68,445,084 and 67,205,321 shares issued and outstanding at march31, 2026 and december31, 2025, respectively
69 67 67 64
Additional paid-in capital
1,529,909 1,491,675 1,454,048 1,241,744
Accumulated other comprehensive income (loss)
444 -796 -926 -2,248
Accumulated deficit
-1,407,516 -1,351,877 -1,304,372 -1,251,468
Total stockholders equity
122,906 139,069 148,817 -11,908
Total liabilities, convertible preferred stock and stockholders equity
442,316 480,196 506,874 372,733
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$278,488K Cash and cashequivalents$62,137K Accounts receivable, net$34,192K Inventory$28,651K Prepaid expenses andother current assets$26,622K Total current assets$430,090K Intangible assets, net$5,106K Right-of-use asset$2,936K Other long-termassets$2,518K Property and equipment,net$1,065K Restricted cash$601K Total assets$442,316K Total liabilities,convertible preferred stock...$442,316K Total liabilities$204,700K Total stockholdersequity$122,906K Series a convertiblepreferred stock, 0.001 par...$114,710K Accumulated deficit-$1,407,516K Total currentliabilities$103,198K Deferred royaltyobligation$98,339K Lease liability,non-current$3,163K Additional paid-in capital$1,529,909K Accumulated othercomprehensive income (loss)$444K Common stock, 0.001 parvalue 120,000,000...$69K Accrued expenses andother current...$80,045K Accounts payable$12,299K Deferred royaltyobligation, current$10,130K Lease liability$676K Deferred revenue$48K

RHYTHM PHARMACEUTICALS, INC. (RYTM)

RHYTHM PHARMACEUTICALS, INC. (RYTM)